TY - JOUR
T1 - Serum leptin levels increase rapidly after initiation of clozapine therapy
AU - Brömel, T.
AU - Blum, W. F.
AU - Ziegler, A.
AU - Schulz, E.
AU - Bender, M.
AU - Fleischhaker, C.
AU - Remschmidt, H.
AU - Krieg, J. C.
AU - Hebebrand, J.
N1 - Funding Information:
We are indebted to the patients who participated in this study. We thank Ms Hanitsch (Gieβen), Ms Stöhr and Ms Finkenstein (Marburg) for their excellent technical assistance. This study was supported by the Deutsche Forschungsgemeinschaft.
PY - 1998
Y1 - 1998
N2 - Weight gain is a major side-effect of treatment with clozapine. In order to investigate the influence of the atypical neuroleptic clozapine on leptin secretion, serum leptin levels were measured in 12 patients at baseline and for a 10-week period after initiation of treatment. Serum clozapine levels and levels of its metabolites were simultaneously assessed. Alterations of body weight and body composition were determined. During the 10-week observation period leptin levels differed significantly from the levels determined at baseline (P < 0.0001). During the first 2 weeks of treatment serum leptin levels at least doubled in eight of the 12 patients. The maximal relative increase over baseline was 536%. Low doses of clozapine were sufficient to induce this effect. Within a 10-week period mean body weight, mean body mass index, mean fat mass and mean lean body mass all increased. Based on the results we suggest that in predisposed individuals clozapine induces an increased appetite; overeating and weight gain can ensue, which in turn underlie elevated leptin secretion.
AB - Weight gain is a major side-effect of treatment with clozapine. In order to investigate the influence of the atypical neuroleptic clozapine on leptin secretion, serum leptin levels were measured in 12 patients at baseline and for a 10-week period after initiation of treatment. Serum clozapine levels and levels of its metabolites were simultaneously assessed. Alterations of body weight and body composition were determined. During the 10-week observation period leptin levels differed significantly from the levels determined at baseline (P < 0.0001). During the first 2 weeks of treatment serum leptin levels at least doubled in eight of the 12 patients. The maximal relative increase over baseline was 536%. Low doses of clozapine were sufficient to induce this effect. Within a 10-week period mean body weight, mean body mass index, mean fat mass and mean lean body mass all increased. Based on the results we suggest that in predisposed individuals clozapine induces an increased appetite; overeating and weight gain can ensue, which in turn underlie elevated leptin secretion.
UR - http://www.scopus.com/inward/record.url?scp=0031983738&partnerID=8YFLogxK
U2 - 10.1038/sj.mp.4000352
DO - 10.1038/sj.mp.4000352
M3 - Journal articles
C2 - 9491817
AN - SCOPUS:0031983738
SN - 1359-4184
VL - 3
SP - 76
EP - 80
JO - Molecular Psychiatry
JF - Molecular Psychiatry
IS - 1
ER -